Liminal Biosciences Inc

-0.13 (-10.16%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)26.81M
Current PEN/A
Forward PE 2.5
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.15 Million
Adjusted EPS-$0.32
See more estimates
10-Day MA$1.33
50-Day MA$1.83
200-Day MA$3.36
See more pivots

Liminal Biosciences Inc Stock, NASDAQ:LMNL

440 Armand-Frappier Boulevard, Suite 300, Laval, Qu?©bec H7V 4B4
Phone: +1.450.781.0115
Number of Employees: 251


Liminal BioSciences, Inc. is a biopharmaceutical corporation. The firm engages in the development of therapeutic products focusing on unmet medical needs in the field of fibrosis, autoimmune disease or inflammation and cancer. It operates through the following segments: Small Molecule Therapeutics and Plasma-derived Therapeutics. The Small Molecule Therapeutics segment focuses on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including conditions of the lung, liver and kidney. The Plasma-derived Therapeutics segment provides efficient extraction and purification of therapeutic proteins from human plasma. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.